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Abstract
Introduction Metallothionein (MT) isoforms I + II are
polypeptides with potent antioxidative and anti-inflammatory
properties. In healthy kidneys, MT-I+II have been described as
intracellular proteins of proximal tubular cells. The aim of the
present study was to investigate whether the renal MT-I+II
expression profile is altered during lupus nephritis.
Methods Immunohistochemistry was performed on renal
biopsies from 37 patients with lupus nephritis. Four specimens
of healthy renal tissue served as controls. Clinicopathological
correlation studies and renal survival analyses were performed
by means of standard statistical methods.
Results Proximal tubules displaying epithelial cell MT-I+II
depletion in combination with luminal MT-I+II expression were
observed in 31 out of 37 of the lupus nephritis specimens, but
not in any of the control sections (P = 0.006). The tubular MT
score, defined as the median number of proximal tubules
displaying this MT expression pattern per high-power
microscope field (40× magnification), was positively correlated
to the creatinine clearance in the lupus nephritis cohort (P =
0.01). Furthermore, a tubular MT score below the median value
of the cohort emerged as a significant predictor of a poor renal
outcome in renal survival analyses. Thus, patients with a tubular
MT score < 1.0 had a 6.2-times higher risk of developing end-
stage renal disease than patients with a tubular MT score ≥ 1.0
(P = 0.03).
Conclusion Lupus nephritis is associated with significant
alterations in renal MT-I+II expression. Our data indicate that
important prognostic information can be deduced from the renal
MT-I+II expression profile in systemic lupus erythematosus
patients with nephritis.
Introduction
Systemic lupus erythematosus (SLE) is an immune-inflamma-
tory disorder characterized by multiorgan involvement and a
chronic relapsing course. Nephritis is a common and serious
manifestation of SLE. More than one-half of all SLE patients
develop nephritis during their course of illness, and 10% to
25% of these patients progress to end-stage renal disease
(ESRD) despite immunosuppressive treatment [1-4]. A central
pathogenic aspect of lupus nephritis is the deposition of
immune complexes within glomeruli and tubules. Subsequent
inflammatory processes involving complement activation, mac-
rophage recruitment, and generation of reactive oxygen spe-
cies cause glomerular damage, increased glomerular
permeability, and proteinuria. Sustained glomerular and inter-
stitial inflammation stimulates fibrogenesis, eventually leading
to renal scarring and compromised renal function [1,5].
Metallothioneins (MTs) are nonenzymatic polypeptides of 6 to
7 kDa that bind heavy metals with high affinity and possess a
range of anti-inflammatory properties [6]. Due to a high
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content of cysteines, MTs are potent antioxidants and provide
protection against reactive oxygen species-induced cellular
damage during experimental inflammation [7-10]. In addition,
MTs have been shown to reduce inflammation through interfer-
ence with activation of cytotoxic T cells and B cells [11,12].
Four major MT subfamilies exist in mammals (MT-I, MT-II, MT-
III, and MT-IV). Human kidneys express MT-I and MT-II, which
have been described as intracellular proteins of proximal tubu-
lar cells [13,14].
The aim of the present study was to investigate whether the
pathogenesis of lupus nephritis involves an altered pattern of
renal MT-I+II expression. To our knowledge, this question has
not been addressed before. We demonstrate that lupus
nephritis is associated with significant alterations in the tubular
MT-I+II expression profile. Furthermore, our data indicate that
important prognostic information can be deduced from the
renal MT-I+II expression pattern in patients with lupus
nephritis.
Materials and methods
Patients and biopsy specimens
Formalin-fixed, paraffin-embedded renal biopsies were
obtained from patients of a previously described historic lupus
nephritis cohort [4]. All patients were diagnosed with lupus
nephritis during the period 1975 to 1995 and met the classifi-
cation criteria of SLE defined by the American College of
Rheumatology [15]. Tissue suitable for experimental immuno-
histochemistry could be retrieved for 37 patients. These biop-
sies were kindly made available from the Departments of
Pathology at Odense University Hospital, Denmark, at Aarhus
University Hospital, Denmark, at Herlev University Hospital,
Denmark, and at The National University Hospital, Rigshospi-
talet, Copenhagen, Denmark. All biopsies had been taken for
diagnostic purposes, and no patients had previously been
diagnosed with lupus nephritis. Samples of normal kidney tis-
sue obtained from four patients with renal cell carcinoma
served as control specimens. In addition, renal biopsies from
five patients suffering from antineutrophil cytoplasmic autoan-
tibody-associated systemic vasculitis (AASV) with glomeru-
lonephritis were retrieved (two patients with Wegener's
granulomatosis, three patients with microscopic polyangiitis).
The following data were registered at the time of biopsy for all
SLE patients: sex, age at time of biopsy, age at time of SLE
diagnosis, date of first renal biopsy, date of onset of nephritis
symptoms (defined as the date of the first observation of per-
sistent proteinuria (> 0.5 g/day), hematuria, and/or cellular
casts), serum creatinine, creatinine clearance, serum albumin,
blood pressure, level of 24-hour urinary protein excretion, a
clinical disease activity score (representing a modified version
of the European Consensus Lupus Activity Measurement [16],
using only the clinical components with unchanged scoring
weights), and a urinary sediment analysis. The urinary sedi-
ment was considered indicative of active renal disease if anal-
ysis showed cellular or granular casts or > 5 erythrocytes per
high-power field. Treatment with cyclophosphamide, azathio-
prine, and high-dose cortico steroids was recorded. The time
from kidney biopsy to development of ESRD (defined as the
need for chronic dialysis or renal transplantation) was known
in all cases. The study baseline was defined as the date of first
renal biopsy. Patients were followed until death or until the end
of 1995. No patients were lost to follow-up.
Standard histopathological analyses
All SLE biopsies were examined (by HS) and classified
according to the World Health Organization (WHO) classifi-
cation criteria for lupus nephritis [17]. Activity index scores
and chronicity index scores were calculated using the scoring
system developed by the US National Institutes of Health [18].
According to this system, active glomerular lesions include
cellular proliferation, fibrinoid necrosis/karyorrhexis, cellular
crescents, hyaline thrombi/wire loops, and leukocyte infiltra-
tion – while mononuclear cell infiltration is considered an
active tubulointerstitial abnormality. Chronic glomerular
lesions encompass glomerular sclerosis and fibrous cres-
cents, while chronic tubulointerstitial changes include intersti-
tial fibrosis and tubular atrophy. Each variable is scored from
zero to three, weighting fibrinoid necrosis/karyorrhexis and
cellular crescents by a factor of two. The biopsies were evalu-
ated without knowledge of clinical data.
Immunohistochemistry
Paraffin-embedded renal biopsies were cut into 5 μm-thick
sections and were processed for immunohistochemistry as
previously described [19,20]. In brief, sections were incu-
bated overnight at 4°C with rabbit anti-MT-I+II, diluted 1:500
[20-23]. The primary antibody was detected using biotinylated
mouse antirabbit IgG (1:400, code B3275; Sigma-Aldrich,
Copenhagen, Denmark), followed by streptavidin–biotin–per-
oxidase complex (StreptABComplex/HRP, code K377; Dako-
patts, Glostrup, Denmark) prepared according to the
manufacturer's recommended dilution. These secondary and
tertiary steps were performed at room temperature for 30 min-
utes. The immunoreaction was visualized using 0.015% H2O2
in 3.3-diaminobenzidine-tetrahydrochloride (DAB)/Tris-buff-
ered saline (TBS: 0.05 M Tris, 0.15 M NaCl, pH 7.4) for 10
minutes at room temperature. To evaluate the extent of non-
specific binding in the immunohistochemical experiments,
control sections were incubated in the absence of primary
antibody.
Evaluation of immunohistochemically stained slides
To obtain an overall impression of the MT-I+II expression pat-
terns, anti-MT-I+II-stained sections were first screened by two
investigators (MF and MP). In the healthy kidney specimens, a
strong MT-I+II staining reaction was observed in the cyto-
plasm of proximal tubular cells. Furthermore, cytoplasmic MT-
I+II staining was seen in the epithelial cells of some collecting
tubules as described below. In the lupus nephritis specimens,Available online http://arthritis-research.com/content/10/4/R76
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MT-I+II staining was also found in the proximal renal tubules.
In a large proportion of these specimens, however, some prox-
imal tubules displayed intense luminal MT-I+II reactivity in
combination with absent or significantly reduced epithelial cell
staining. The number of cross-sectioned proximal tubules dis-
playing the latter pattern of anti-MT-I+II reactivity was deter-
mined in a sequence of 3 to 60 consecutive high power fields
(40× magnification), depending on the size of the individual
biopsy. The only field adjustments were made to avoid large
vessels and glomeruli.
For semiquantitative analyses, each cross-sectioned proximal
tubule displaying significant luminal MT-I+II reactivity in combi-
nation with reduced/absent staining of the lining epithelial
cells was scored one, while cross-sectioned proximal tubules
in which the MT-I+II staining was observed exclusively/pre-
dominantly in the cytoplasm of the epithelial cells were scored
zero. As a conservative approach, tubules that did not clearly
display one of these morphologies were also scored zero. The
tubular MT score of the individual biopsy specimens was
defined as the median score obtained according to this scor-
ing system per visual field at 40× magnification.
Most of the lupus nephritis biopsies consisted mainly of corti-
cal renal tissue. Consequently, the MT-I+II expression in col-
lecting tubules could not be systematically examined in these
specimens. In all biopsies, glomerular cross-sections were
also evaluated for MT-I+II reactivity, and the median number of
MT-I+II-positive cells was determined.
All biopsies were scored by the same investigator (MF) and
were analyzed without knowledge of clinical or standard his-
topathological data. The scorings were subsequently vali-
dated by another investigator (CBA).
Visualization
Sections were examined on an Axioplan plus light microscope
(Zeiss, Göttingen, Germany). Images were recorded using a
digital camera (Coolsnap 1.2; RS Photometrics, Tucson, AZ,
USA).
Statistics
The cumulative incidence of ESRD was calculated using life
tables and the Kaplan–Meier method. The equality of cumula-
tive incidence curves was tested by the log-rank test. Event
rates were related to the total number of person-years of
observation, and rate ratios of event rates were calculated in
stratified analyses. Comparison of continuous data was per-
formed using the Mann–Whitney rank-sum test. Spearman's
rank correlation test was used in correlation studies.
In all analyses, P < 0.05 (two-tailed) was considered statisti-
cally significant. The statistical analyses were performed on a
computer using SPSS version 9.0 for Windows (SPSS, Chi-
cago, IL, USA).
Ethics
The present study was approved by the local ethics committee
(journal number 01 310445) and by the Danish Data Protec-
tion Agency (journal number 2006060030A).
Results
Basic clinical and histopathological findings
Clinical data of the 37 SLE patients are summarized in Table
1. Thirty-two of the 37 patients were women. Seven patients
progressed to ESRD during 161 patient-years of observation,
and the cumulative incidence of ESRD after 1 year, 5 years,
and 10 years was 6%, 25%, and 36%, respectively. Twenty-
two patients (59%) received treatment with cyclophospha-
mide during their course of illness, a similar number (59%) of
patients were treated with azathioprine, and five (13%)
patients were subjected to treatment with high-dose corticos-
Table 1
Clinical data of 37 patients with lupus nephritis at the time of first renal biopsy
Number of patients Median Lower quartile Upper quartile
Age (years) 37 29.6 19.6 46.5
Duration of systemic lupus erythematosus before biopsy (years) 37 0.4 0.0 7.6
Duration of follow-up (years)a 37 5.0 1.1 8.0
Creatinine clearance (% of expected) 37 77 60 100
Serum albumin (μmol/l) 37 411 304 498
24-hour urinary protein excretion (g) 37 4.9 2.1 15.1
Systolic blood pressure (mmHg) 36 130 116 160
Diastolic blood pressure (mmHg) 36 90 71 90
aDuration of follow-up after first renal biopsy.Arthritis Research & Therapy    Vol 10 No 4    Faurschou et al.
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teroids only. In all cases, immunosuppressive treatment was
started or intensified within 1 month following renal biopsy,
and no patients received intensive immunosuppressive treat-
ment before renal biopsy was performed.
Four patients (11%) presented with WHO class II glomeru-
lonephritis, three patients (8%) with WHO class III glomeru-
lonephritis, 27 patients (73%) displayed WHO class IV
histopathology, and three patients were diagnosed with WHO
class V glomerulonephritis (8%). The median histological
activity index score in the cohort was 5.0 (range = 0 to 14),
while the median chronicity index score was 1.0 (range = 0 to
9). The median activity index score was significantly higher for
patients presenting with WHO class IV glomerulonephritis
(median activity index score = 7.0 (range = 2 to 14)) than for
patients with other WHO classes of nephritis (median activity
index score = 1.5 (range = 0 to 4); P < 0.0001). In contrast,
the median chronicity index score was not significantly higher
in patients with WHO class IV nephritis (median chronicity
index score = 1.0 (range = 0 to 9)) than in patients displaying
other renal histopathologies (median chronicity index score =
0.0 (range = 0 to 3); P = 0.21).
Metallothionein expression in healthy kidneys, lupus 
nephritis, and AASV-associated glomerulonephritis
Anti-MT-I+II staining of control specimens confirmed that MT-
I+II are expressed in the cytoplasm of proximal tubular cells
under normal conditions (Figure 1a) [13,14]. A concurrent
staining reaction was observed frequently in material radiating
from the brush border of the tubular epithelium into the tubular
lumen. In all control specimens, however, the strongest anti-
MT-I+II reactivity was consistently observed in the tubular epi-
thelium, and no proximal tubules displayed significant luminal
anti-MT-I+II reactivity in combination with reduced or absent
epithelial cell staining. These findings are similar to observa-
tions previously reported by Nartey and colleagues [13].
Three of the four control sections contained enough medullary
renal tissue for an examination of medullary structures to be
performed. As a novel finding [13,14], we detected significant
epithelial cell MT-I+II staining in the collecting tubules of these
specimens (Figure 1b). The MT-I+II staining observed in col-
lecting tubules was frequently weaker than the staining reac-
tion observed in proximal tubules, and some cross-sectioned
collecting tubules were MT-I+II-negative. Moreover, while the
epithelial cells of some collecting tubules displayed a homoge-
neous cytoplasmic MT-I+II staining reaction (Figure 1b), the
MT-I+II staining observed in other collecting tubules was con-
fined to the cytoplasm adjacent to the luminal membrane (data
not shown). Glomeruli and other segments of the nephron
were consistently MT-I+II-negative. Furthermore, no significant
MT-I+II staining was observed in the renal interstitium (Figure
1a, b).
Figure 1
Localization of metallothionein (MT) isoforms I + II in healthy kidneys  and in lupus nephritis Localization of metallothionein (MT) isoforms I + II in healthy kidneys 
and in lupus nephritis. Representative results of immunohistochemical 
analyses. (a) Healthy renal tissue. CytoplasmicMT-I+II staining is seen 
in proximal tubular cells. Concurrent MT-I+II staining is frequently 
observed in material radiating from the epithelial brush border into the 
tubular lumen. No staining is observed in glomeruli. (b) Inner medullary 
zone of healthy kidney. MT-I+II staining is seen in the epithelium of the 
collecting tubules but not in cross-sectioned thin segments of Henle's 
loop. (c) Renal tissue from patient with lupus nephritis and a tubular MT 
score of zero as defined in the text. Cytoplasmic MT-I+II staining is 
observed in proximal tubular cells. (d) Renal tissue from another patient 
with lupus nephritis. Intense luminal MT-I+II staining with concomitant 
epithelial cell MT-I+II depletion is observed in several cross-sectioned 
proximal tubules. Glomeruli are MT-I+II-negative. (e) Lupus nephritis. 
Same findings as in (d). (f) Lupus nephritis. Some proximal tubules dis-
play pronounced luminal MT-I+II staining in combination with MT-I+II 
depletion of the lining epithelial cells (black arrows). In other tubules, 
some epithelial cells display cytoplasmic MT-I+II staining (white 
arrows). (g) Lupus nephritis. Several cross-sectioned proximal tubules 
with predominantly luminal MT-I+II staining are shown. As in (f), some 
tubules display MT-I+II depletion of the epithelium (black arrows). In 
other tubules, cytoplasmic MT-I+II staining is seen in a proportion of the 
epithelial cells (white arrows). (h) Pauci-immune glomerulonephritis in 
Wegener's granulomatosis. Two tubules with a predominantly luminal 
MT-I+II expression pattern are marked (arrows).Available online http://arthritis-research.com/content/10/4/R76
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In six out of the 37 lupus nephritis specimens, intense cyto-
plasmic MT-I+II staining was observed in the epithelial cells lin-
ing the proximal tubules (Figure 1c). The MT-I+II staining
pattern observed in these biopsies did not differ significantly
from the pattern observed in the control specimens. In the
remaining lupus nephritis biopsies, we noted the presence of
proximal tubules displaying low to absent epithelial MT-I+II
staining in combination with strong staining of the tubular
lumen. In these tubules, the MTs seemed to be present in the
tubular lumen as extracellular proteins (Figures 1d to 1g).
Only nine (24%) of the lupus nephritis biopsies contained sig-
nificant amounts of medullary renal tissue. In these specimens,
collecting tubules displayed the same epithelial MT-I+II
expression pattern as observed in the control biopsies (data
not shown). Glomeruli and interstitial structures were MT-I+II-
negative in all lupus nephritis specimens (Figure 1d to 1f).
To evaluate whether similar changes in renal MT-I+II expres-
sion occur in the setting of other inflammatory nephropathies,
we finally studied the tubular MT-I+II expression pattern in
biopsies from five patients with AASV and glomerulonephritis.
In four out of five of these biopsies, we observed the occa-
sional presence of tubules displaying the same alterations in
MT-I+II expression as described above (Figure 1h).
Metallothionein scores and correlation studies
The median tubular MT score was significantly higher in the
lupus nephritis specimens (median tubular MT score of the 37
lupus nephritis biopsies = 1.0 (range = 0.0 to 6.8)) than in the
control specimens (median tubular MT score of the four con-
trol specimens = 0.0 (range = 0); P = 0.006) and in the AASV
biopsies (median tubular MT score of the five AASV speci-
mens = 0.16 (range = 0.0 to 0.27); P = 0.04). Among the SLE
patients, the median tubular MT score tended to be lower for
patients with WHO class IV nephritis than for patients present-
ing with other WHO histopathologies (median tubular MT
score for 27 patients with WHO class IV nephritis = 0.8
(range = 0.0 to 6.8); median tubular MT score for the 10 other
patients = 1.4 (range = 0.1 to 3.6)). This difference was not,
however, statistically significant (P = 0.07).
To examine potential associations between the tubular MT
score and standard clinicopathological variables in the lupus
nephritis cohort, we investigated whether the subset of lupus
patients with tubular MT score = 0 (n = 6) differed from
patients with tubular MT score > 0 (n = 31) with regards to
baseline levels of selected variables reflecting renal function,
including creatinine clearance, level of 24-hour urinary protein
excretion, serum albumin, activity index score, chronicity index
score, and blood pressure (Table 2). This analysis showed that
patients presenting with a tubular MT score of zero had a sig-
nificantly lower median creatinine clearance than the rest of
the patients. To further analyze the association between the
tubular MT score and the creatinine clearance, we examined
whether these variables were correlated to each other in the
lupus cohort other using Spearman's rank correlation test. In
this analysis, a statistically significant, positive correlation was
found between the tubular MT score and the creatinine clear-
ance (Figure 2).
Risk factors for end-stage renal disease
The patients in the present cohort were part of a larger cohort
of lupus nephritis patients [4]. In the original cohort, several
clinical and histological findings emerged as significant univar-
iate predictors of ESRD (duration of nephritis symptoms prior
to biopsy ≥ 6 months, serum creatinine ≥ 140 μmol/l, WHO
class IV nephritis, chronicity index score ≥ 4, glomerular scle-
rosis, fibrous crescents, interstitial fibrosis, and tubular
atrophy).
In the much smaller cohort of the present study, only a chro-
nicity index score ≥ 4 and a index score for interstitial fibrosis
≥ 2, i.e., histological findings reflecting chronic renal damage,
were identified as significant risk factors for ESRD in dichot-
Table 2
Median values of selected clinical variables in a cohort of 37 patients with lupus nephritis
Variable MT score = 0 MT score > 0 P valuea
Creatinine clearance (% of expected) 37.5 (10.0 to 75.0) 89.0 (3.0 to 201.0) 0.006
24-hour urinary protein excretion (g) 7.6 (2.7 to 21.8) 4.8 (0.2 to 31.9) 0.3
Serum albumin (μmol/l) 265.5 (60 to 480) 420 (150 to 615) 0.06
Activity index score 3.0 (2 to 10) 5.0 (0 to 14) 0.8
Chronicity index score 2.0 (0 to 7) 1.0 (0 to 9) 0.5
Systolic blood pressure (mmHg) 125 (105 to 200) 135 (100 to 200) 0.5
Diastolic blood pressure (mmHg) 85 (70 to 110) 90 (60 to 160) 0.9
Data presented as the median (range). Patients with a tubular metallothionein (MT) score = 0 (n = 6) versus patients with a tubular MT score > 0 
(n = 31). MT score as defined in text. aMann–Whitney rank-sum test.Arthritis Research & Therapy    Vol 10 No 4    Faurschou et al.
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omized analyses of standard clinical and histological variables
(Table 3). The following clinicopathological variables were not
associated with an increased risk of progression towards
ESRD: sex; age at time of biopsy; duration of nephritis symp-
toms prior to biopsy ≥ 6 months; treatment without cyclophos-
phamide; treatment without azathioprine; modified European
Consensus Lupus Activity Measurement score ≥ 4; hypercre-
atininaemia (serum creatinine ≥ 140 μmol/l); hypoalbuminae-
mia (serum albumin < 300 μmol/l); active urinary sediment,
24-hour urinary protein excretion ≥ 10 g; systolic blood
pressure > 160 mmHg; diastolic blood pressure > 110
mmHg; tubular MT score = 0; WHO class IV histopathology;
high activity index scores (cutoff levels tested: ≥ 5, ≥ 7, ≥ 10);
and index scores for glomerular sclerosis, fibrous crescents,
and tubular atrophy ≥ 2.
Interestingly, a tubular MT score below the median value of the
cohort emerged as the most powerful predictor of a poor renal
outcome among the variables tested. Thus, patients with a
tubular MT score < 1.0 had a 6.2-times higher risk of progres-
sion towards ESRD than the rest of the patients (Table 3).
Cumulative renal survival curves are shown in Figure 3.
Discussion
Proximal tubules are known to elicit a variety of responses to
protein overload during proteinuric nephropathies. Exposure
to high protein concentrations stimulates proximal tubular cells
to secrete proinflammatory mediators, including monocyte
chemoattractant protein 1 [24], regulation upon activation,
normal T-cell expressed and secreted (RANTES) [25], IL-8
[26], complement factor C3 [27], and transforming growth
factor beta [28]. During lupus nephritis, proximal tubules have
been shown to alter their expression of several molecules
involved in inflammatory processes, including intracellular
adhesion molecule 1, CD40, and Toll-like receptor 9 [29,30].
In the present study, we demonstrate that proximal tubules
exposed to the inflammatory and proteinuric conditions
associated with lupus nephritis also display a significantly
altered expression pattern of MT-I+II. By immunohistochemical
analyses, we noted a relatively high frequency of cross-sec-
tioned proximal tubules showing luminal MT-I+II expression
with concomitant epithelial cell MT-I+II depletion in kidney
biopsies from lupus nephritis patients. Similar changes in renal
MT-I+II expression were not observed in biopsies of healthy
renal tissue. Importantly, the tubular MT score, reflecting the
incidence of proximal tubules displaying these changes in MT-
I+II expression, was positively correlated to the creatinine
clearance in the SLE cohort, and lupus patients with a tubular
MT score of zero presented with a significantly lower median
creatinine clearance than the rest of the patients. Moreover, a
tubular MT score < 1.0 was identified as a strong predictor of
ESRD in renal survival analyses. A low tubular MT score was
therefore associated with impaired renal function at the time of
first kidney biopsy and with an increased risk of a poor renal
outcome in the present SLE cohort, indicating that renal MTs
exert important renoprotective functions in the lumen of proxi-
mal tubules during lupus nephritis.
The present study was based on a historic cohort of patients
and has several limitations. Due to the retrospective nature of
the investigations, we were unable to obtain patient material
such as serum, urine, or additional renal tissue for further
experimental analyses. We were therefore prevented from
investigating whether the tubular MT score was correlated to
the level of urinary MT-I+II excretion or to the serum concen-
tration of these MTs. Consequently, the present study does
not elucidate whether the urinary MT concentration can be
used as a biomarker for active nephritis in SLE patients in the
same way as previously demonstrated for molecules such as
vascular cell adhesion molecule 1, P-selectin, soluble TNF
receptor 1 and chemokine (C–X–C motif) ligand 16 [31,32].
Furthermore, we were unable to investigate the origin of the
MTs observed in the lumen of proximal tubules during lupus
nephritis. In the examined nephritis specimens, luminal MT-I+II
expression was consistently associated with MT-I+II depletion
of the adjacent tubular epithelium, but not with enhanced MT-
I+II expression in other nephron segments or in the renal inter-
stitium. Moreover, light microscopic analyses suggested that
MT-I+II are present in the lumen of proximal tubules as extra-
cellular proteins. Together, these findings strongly indicate
that the MTs observed in the lumen of proximal tubules were,
at least in part, secreted from adjacent tubular cells and not
simply derived from plasma via glomerular ultrafiltration. Fur-
ther studies are needed, however, to determine whether prox-
imal tubular cells secrete MT-I+II to the tubular lumen in the
Figure 2
Tubular metallothionein score versus creatinine clearance Tubular metallothionein score versus creatinine clearance. Scatterplot 
of tubular metallothionein (MT) score versus creatinine clearance in a 
cohort of 37 patients with lupus nephritis. A statistically significant, 
positive correlation was found between these variables using Spear-
man's rank correlation test. rs, Spearman's rank correlation coefficient.Available online http://arthritis-research.com/content/10/4/R76
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setting of lupus nephritis – and, if so, to identify the stimuli that
trigger the secretion.
Intriguingly, our analyses demonstrate that proximal tubules do
not always display intraluminal MT-I+II immunostaining during
lupus nephritis, suggesting that this alteration in renal MT dis-
tribution requires or can be blocked by as yet undefined stim-
uli. To this end, it could be hypothesized that proximal tubular
cells secrete MTs in response to the presence of harmful sub-
stances delivered to the tubular lumen from the inflamed
glomerulus, but that this secretion can be inhibited by other
intracellular or extracellular signals associated with renal
inflammation. Although the present study was not designed to
investigate the extent to which similar changes in renal MT
expression occur during other inflammatory nephropathies,
our analyses indicate that the same morphological tubular
alterations are seen in AASV glomerulonephritis. This observa-
tion suggests that the mechanisms responsible for inducing
the observed alterations in the tubular MT expression profile
are not specific for lupus nephritis, but are probably evoked by
renal inflammation per se.
A range of histological features has been shown to influence
the prognosis in lupus nephritis. Frequently reported histolog-
ical predictors of a poor renal outcome include WHO class IV
histopathology [4,33,34], high activity index scores and chro-
nicity index scores [4,18,35], high index scores for cellular
crescents [35,36], glomerular sclerosis [4,35], interstitial
fibrosis [4,35-37], and tubular atrophy [4,35]. Thus, histologi-
cal variables identified as risk factors of ESRD typically reflect
either active inflammation or the late-stage, degenerative con-
sequences of inflammation. Here, we provide evidence that
the renal expression pattern of MT-I+II, i.e., proteins with
potent anti-inflammatory and antioxidative properties, also car-
ries prognostic information in lupus nephritis. The findings of
our study add to the growing amount of experimental data sug-
gesting that MT-I+II exert important functions not only as intra-
cellular proteins, as previously suggested [38,39], but also
after secretion from MT-producing cells [9,40].
Furthermore, our study raises a number of new questions.
Based on the known functional repertoire of MT-I+II, it is
tempting to speculate that MT-I+II protect the proximal tubular
epithelium from reactive oxygen species and other cytotoxic
substances after secretion to the tubular lumen as outlined
above. Nevertheless, the mechanisms by which these MTs
provide renoprotection during lupus nephritis remain to be
defined. It also remains to be clarified to what extent the
observed changes in tubular MT-I+II expression are evoked in
the setting of other inflammatory nephropathies. Finally, from a
therapeutic perspective it would be of great interest to investi-
gate whether treatment with exogenous MT-I+II could modify
the course of lupus nephritis in animal models.
Conclusion
Our study provides the first description of renal MT-I+II expres-
sion during lupus nephritis. Compared with the MT-I+II expres-
sion pattern observed in healthy renal tissue, characteristic
alterations in the tubular MT expression profile were found in
most of the examined lupus nephritis specimens. In renal sur-
vival analyses, these alterations were found to be of prognostic
significance.
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